Evidence map›Paper›PMID 37165760›Full record

ArticleCancer science2023

Human resources for administrative work to carry out a comprehensive genomic profiling test in Japan.

Hidenori Kage, Katsutoshi Oda, Manabu Muto, Katsuya Tsuchihara, Natsuko Okita, Yusuke Okuma, Junko Kikuchi, Hidekazu Shirota, Hideyuki Hayashi, Toshio Kokuryo and 10 more

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 12 institutions in 2 countries.

Hidenori KageDepartment of Clinical Genomics, The University of Tokyo Hospital, Tokyo, Japan.ORCID https://orcid.org/0000-0003-3658-4442
Katsutoshi OdaDepartment of Clinical Genomics, The University of Tokyo Hospital, Tokyo, Japan.ORCID https://orcid.org/0000-0002-2468-9573
Manabu MutoDepartment of Therapeutic Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan.ORCID https://orcid.org/0000-0002-3127-8203
Katsuya TsuchiharaDepartment of Genetic Medicine and Services, National Cancer Center Hospital East, Chiba, Japan.ORCID https://orcid.org/0000-0001-7507-2349
Natsuko OkitaCenter for Cancer Genomics and Advanced Therapeutics, National Cancer Center, Tokyo, Japan.
Yusuke OkumaCenter for Cancer Genomics and Advanced Therapeutics, National Cancer Center, Tokyo, Japan.
Junko KikuchiDivision of Clinical Cancer Genomics, Hokkaido University Hospital, Sapporo, Japan.
Hidekazu ShirotaDepartment of Clinical Oncology, Tohoku University Hospital, Sendai, Japan.ORCID https://orcid.org/0000-0001-9154-9004
Hideyuki HayashiGenomics Unit, Keio Cancer Center, Keio University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0002-4974-8015
Toshio KokuryoDivision of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID https://orcid.org/0000-0001-7176-7581
Daisuke SakaiCenter for Cancer Genomics and Personalized Medicine, Osaka University Hospital, Suita, Japan.
Akira HirasawaDepartment of Clinical Genomic Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan.ORCID https://orcid.org/0000-0003-4124-5488
Makoto KuboDepartment of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Hirotsugu KenmotsuDivision of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.ORCID https://orcid.org/0000-0003-0590-9259
Nana AkiyamaDepartment of Clinical Genomics, The University of Tokyo Hospital, Tokyo, Japan.
Aya Shinozaki-UshikuDepartment of Clinical Genomics, The University of Tokyo Hospital, Tokyo, Japan.
Masahiko TanabeDepartment of Breast and Endocrine Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0002-6558-4399
Tetsuo UshikuDepartment of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Kiyoshi MiyagawaDepartment of Clinical Genomics, The University of Tokyo Hospital, Tokyo, Japan.
Yasuyuki SetoDepartment of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
University of Tokyo Hospital · JPThe University of Tokyo · JPHokkaido University Hospital · JPKeio University · JPKyoto University · JPKyushu University · JPNagoya University · JPNational Cancer Center Hospital East · JPOkayama University · JPOsaka University Hospital · JPShizuoka Cancer Center · JPTohoku University Hospital · JP

Funding

Ministry of Health, Labour and Welfare 20EA1006
6 · The paper itself

Abstract

Comprehensive genomic profiling (CGP) tests have been nationally reimbursed in Japan since June 2019 under strict restrictions, and over 46,000 patients have taken the test. Core Hospitals and Designated Hospitals host molecular tumor boards, which is more time-consuming than simply participating in them. We sent a questionnaire to government-designated Cancer Genomic Medicine Hospitals, including all 12 Core Hospitals, all 33 Designated Hospitals, and 117 of 188 Cooperative Hospitals. The questionnaire asked how much time physicians and nonphysicians spent on administrative work for cancer genomic medicine. For every CGP test, 7.6 h of administrative work was needed. Physicians spent 2.7 h/patient, while nonphysicians spent 4.9 h/patient. Time spent preparing for molecular tumor boards, called Expert Panels, was the longest, followed by time spent participating in Expert Panels. Assuming an hourly wage of ¥24,000/h for physicians and ¥2800/h for nonphysicians, mean labor cost was ¥78,071/patient. On a monthly basis, more time was spent on administrative work at Core Hospitals compared with Designated Hospitals and Cooperative Hospitals (385 vs. 166 vs. 51 h/month, respectively, p < 0.001). Consequently, labor cost per month was higher at Core Hospitals than at Designated Hospitals and Cooperative Hospitals (¥3,951,854 vs. ¥1,687,167 vs. ¥487,279/month, respectively, p < 0.001). Completing a CGP test for a cancer patient in Japan is associated with significant labor at each hospital, especially at Core Hospitals. Streamlining the exchange of information and simplifying Expert Panels will likely alleviate this burden.

Indexed as

NeoplasmsGenomicsHospitalsHumansJapanWorkforceadministrative personnelcancer genomic medicinecomprehensive genomic profilingcost analysisworkforce

Identifiers

PMID37165760
PMCPMC10323090
OpenAlexW4376133257

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.